Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: Evidence from 44 US states

被引:6
|
作者
Bruzelius, Emilie [1 ]
Cerda, Magdalena [2 ]
Davis, Corey S. [2 ,3 ]
Jent, Victoria [2 ]
Wheeler-Martin, Katherine [2 ]
Mauro, Christine M. [4 ]
Crystal, Stephen [5 ]
Keyes, Katherine M. [1 ]
Samples, Hillary [5 ]
Hasin, Deborah S. [6 ]
Martins, Silvia S. [1 ]
机构
[1] Columbia Univ, Dept Epidemiol, 722 W 168th St, New York, NY 10032 USA
[2] NYU Grossman Sch Med, Dept Populat Hlth, 180 Madison Ave 4th Floor, New York, NY 10016 USA
[3] Network Publ Hlth Law, 7101 York Ave South, Edina, MN 55435 USA
[4] Columbia Univ, Dept Biostat, 722 W 168th St, New York, NY 10032 USA
[5] Rutgers State Univ, 112 Paterson St, New Brunswick, NJ 08901 USA
[6] Columbia Univ, Dept Psychiat, 722 W 168th St,Room 228F, New York, NY 10032 USA
关键词
Naloxone; Adolescent; Harm reduction; Injection drug use; Heroin; Policy analysis; UNITED-STATES; RISK BEHAVIOR; PRESCRIPTION; STUDENTS; ACCESS; LAWS;
D O I
10.1016/j.drugpo.2023.103980
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Naloxone distribution is central to ongoing efforts to address the opioid overdose crisis. Some critics contend that naloxone expansion may inadvertently promote high-risk substance use behaviors among adoles-cents, but this question has not been directly investigated. Methods: We examined relationships between naloxone access laws and pharmacy naloxone distribution with lifetime heroin and injection drug use (IDU), 2007-2019. Models generating adjusted odds ratios (aOR) and 95% confidence intervals (CI) included year and state fixed effects, controlled for demographics and sources of variation in opioid environments (e.g., fentanyl penetration), as well as additional policies expected to impact substance use (e.g., prescription drug monitoring). Exploratory and sensitivity analyses further examined nalox-one law provisions (e.g., third-party prescribing) and applied e-value testing to assess vulnerability to unmeasured confounding. Results: Adoption of any naloxone law was not associated with changes in adolescent lifetime heroin or IDU. For pharmacy dispensing, we observed a small decrease in heroin use (aOR: 0.95 [CI: 0.92, 0.99]) and a small increase in IDU (aOR: 1.07 [CI: 1.02, 1.11]). Exploratory analyses of law provisions suggested that third-party prescribing (aOR: 0.80, [CI: 0.66, 0.96]) and non-patient-specific dispensing models (aOR: 0.78, [CI: 0.61, 0.99]) were associated with decreased heroin use but not decreased IDU. Small e-values associated with the pharmacy dispensing and provision estimates indicate that unmeasured confounding may explain observed findings. Conclusion: Naloxone access laws and pharmacy naloxone distribution were more consistently associated with decreases rather than increases in lifetime heroin and IDU among adolescents. Our findings therefore do not support concerns that naloxone access promotes high-risk adolescent substance use behaviors. As of 2019, all US states have adopted legislation to improve naloxone access and facilitate use. However, further removal of adolescent naloxone access barriers is an important priority given that the opioid epidemic continues to affect people of all ages
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Naloxone Expansion is Not Associated With Increases in Adolescent Heroin Use and Injection Drug Use: Evidence From 44 US States
    Bruzelius, Emilie
    Cerda, Magdalena
    Davis, Corey
    Jent, Victoria
    Wheeler-Martin, Katherine
    Mauro, Christine
    Crystal, Stephen
    Keyes, Katherine
    Samples, Hillary
    Hasin, Deborah
    Martins, Silvia
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [2] Trends in Adolescent Heroin and Injection Drug Use in Nine Urban Centers in the US, 1999-2017
    Brighthaupt, Sherri-Chanelle
    Schneider, Kristin E.
    Johnson, Julie K.
    Jones, Abenaa A.
    Johnson, Renee M.
    [J]. JOURNAL OF ADOLESCENT HEALTH, 2019, 65 (02) : 210 - 215
  • [3] Nonmedical Use of Prescription Opioids, Heroin Use, Injection Drug Use, and Overdose Mortality in US Adolescents
    Bohm, Michele K.
    Clayton, Heather B.
    [J]. JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2020, 81 (04) : 484 - 488
  • [4] Factors associated with adolescent initiation of injection drug use
    Fuller, CM
    Vlahov, D
    Arria, AM
    Ompad, DC
    Garfein, R
    Strathdee, SA
    [J]. PUBLIC HEALTH REPORTS, 2001, 116 : 136 - 145
  • [5] Is inhalant use a risk factor for heroin and injection drug use among adolescents in the United States?
    Wu, Li-Tzy
    Howard, Matthew O.
    [J]. ADDICTIVE BEHAVIORS, 2007, 32 (02) : 265 - 281
  • [6] Do naloxone access laws affect perceived risk of heroin use? Evidence from national US data
    Kelly, Brian C.
    Vuolo, Mike
    [J]. ADDICTION, 2022, 117 (03) : 666 - 676
  • [7] Reductions in heroin use are not associated with increases in other drug use: 2-year findings from the Australian Treatment Outcome Study
    Darke, Shane
    Williamson, Anna
    Ross, Joanne
    Teesson, Maree
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2006, 84 (02) : 201 - 205
  • [8] Heroin Use, Non-Medical Prescription Opioid Use, and Injection Drug Use Among Urban High School Students Across the US
    Byregowda, Himani
    Powell, Terrinieka
    Wang, Xinzi
    Linton, Sabriya
    Johnson, Renee
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [9] Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health
    Ali, Mir M.
    Dowd, William N.
    Classen, Timothy
    Mutter, Ryan
    Novak, Scott P.
    [J]. ADDICTIVE BEHAVIORS, 2017, 69 : 65 - 77
  • [10] Young adults' opioid use trajectories: From nonmedical prescription opioid use to heroin, drug injection, drug treatment and overdose
    Guarino, Honoria
    Mateu-Gelabert, Pedro
    Teubl, Jennifer
    Goodbody, Elizabeth
    [J]. ADDICTIVE BEHAVIORS, 2018, 86 : 118 - 123